Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
The cell and gene therapy sectors are growing exponentially, with new players emerging daily and much progress being made both in and out of the lab. CGTLive’s Around the Helix is your chance to catch up with the latest news in cell and gene therapies, including partnerships, pipeline updates, and more.
The CIFFREO trial is underway in 11 countries but was halted in December 2021 amid safety concerns, including the death of a participant in a phase 1b study in the non-ambulatory cohort.
The FDA has granted a Fast Track Designation to the therapeutic vaccine SQZ-PBMC-HPV as a potential treatment for patients with advanced or metastatic HPV16+ solid tumors.
The investigational, AAV-based gene therapy delivers a functional copy of the progranulin GRN gene, helping to restore normal progranulin levels in patients who have an autosomal dominant mutation in the gene, which is one of 3 linked to familiar cases of the neurodegenerative disease.
The US FDA has granted regenerative medicine advanced therapy (RMAT) to Autolus Therapeutics’ investigational gene-edited cell therapy, obecabatagene autoleucel (obe-cel), an autologous CD19-directed CAR T-cell therapy currently being evaluated in the phase 2 FELIX clinical trial in patients with relapsed or refractory B-acute lymphocytic leukemia (B-ALL).
EDIT-301, an investigational, gene-edited medicine for the treatment of beta thalassemia, was previously granted rare pediatric disease designation for the treatment of sickle cell disease.
Solid Bio will reduce its headcount by 35% in the wake of a corporate refocus on its 2 leading DMD gene therapy programs, SGT-001 and SGT-003.
Cytovia announced that it has entered into a definitive business combination agreement with Isleworth Healthcare Acquisition Corp., , which will help which will help provide Cytovia with capital for up to 2 years to further develop its gene-edited iNK and Flex-NK cell engager technologies.
Allogene's TurboCAR T-cell product ALLO-605 has been granted orphan drug designation from the FDA for the treatment of multiple myeloma, following a fast track designation recieved in Q2 2021.
Ocugen received a positive review from a data safety monitoring board, clearing them to continue enrollment of patients in their phase 1/2 trial evaluating OCU400, a gene therapy for retinitis pigmentosa.